Center for Biotechnology – Stony Brook University

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => 
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 4804
                    [post_author] => 4
                    [post_date] => 2025-03-20 12:10:54
                    [post_date_gmt] => 2025-03-20 16:10:54
                    [post_content] => 
The Center for Biotechnology is pleased to announce a request for proposals for our Research Evaluation and Commercialization Hub (REACH) award program. Awards will be in two categories: Feasibility ($50k/12mo) and Proof of Concept ($100K/12 mo.) Details on the full funding program overview and proposal guidelines can be found here.



The development of promising innovations often stalls due to limited early-stage funding to address translational uncertainties. The Center for Biotechnology's Research Evaluation and Commercialization Hub (REACH) award program bridges the translation gap between biomedical discovery and their development toward commercial goals. Program funding is intended to determine feasibility, develop proof-of-concept, and ultimately lead to follow-on funding, a strategic partnership, or company formation.



The REACH program supports faculty and postdoctoral researchers in translating bio-based, bio-convergence, and bio-medical research discoveries by providing targeted funding and strategic guidance to bridge the translation gap between discovery and development for commercialization.



Application Deadline: May 15, 2025, 5pm ET



Learn more about the program, get information session details and access the full request for proposals here: https://centerforbiotechnology.org/what-we-do/technology-development/reach/

                    [post_title] => Funding Opportunity: Research Evaluation and Commercialization Hub (REACH)Awards
                    [post_excerpt] => The Center for Biotechnology is pleased to announce a request for proposals for our REACH award program.  Awards will be in two categories: Feasibility ($50k/12mo) and Proof of Concept ($100K/12 mo.) 
                    [post_status] => publish
                    [comment_status] => open
                    [ping_status] => open
                    [post_password] => 
                    [post_name] => news-reach25
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-03-24 12:11:36
                    [post_modified_gmt] => 2025-03-24 16:11:36
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://centerforbiotechnology.org/?p=4804
                    [menu_order] => 0
                    [post_type] => post
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [1] => WP_Post Object
                (
                    [ID] => 4488
                    [post_author] => 4
                    [post_date] => 2024-10-24 10:45:00
                    [post_date_gmt] => 2024-10-24 14:45:00
                    [post_content] => 
Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.



The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.



New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.



A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment will provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.



New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.



Read the press release of Governor Hochul's announcement here:
https://www.governor.ny.gov/news/governor-hochul-launches-next-phase-long-islands-nation-leading-cell-and-gene-therapy

                    [post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park.
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => open
                    [ping_status] => open
                    [post_password] => 
                    [post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-02-26 16:35:20
                    [post_modified_gmt] => 2025-02-26 21:35:20
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://centerforbiotechnology.org/?p=4488
                    [menu_order] => 0
                    [post_type] => post
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [2] => WP_Post Object
                (
                    [ID] => 3225
                    [post_author] => 3
                    [post_date] => 2019-04-05 19:35:45
                    [post_date_gmt] => 2019-04-05 19:35:45
                    [post_content] => Join the Center for Biotechnology for Roche Oncology Strategic Interests Presentation on Monday April 15, 2019.

Fiona Mack, PhD, Director External Innovation, Pharmaceutical Research and Early Development for the Roche Innovation Center New York will be at Stony Brook University Medical Center to present Roche’s strategic interests in Oncology, the process for asset evaluation and the various partnership models available to support discovery and early development programs. Fiona will also discuss Roche’s approach to investing in emerging novel therapeutics utilizing case studies as examples.

April 15, 2019
10am-11am
Radiation Oncology Conference Room (HOS L2-664)
Stony Brook University Medical Center Level 2

Seating is limited. If you are interested in attending please contact Emily Kao at emily.kao@stonybrook.edu

How to get to Stony Brook University Hospital Radiation Oncology Conference Room
To access the Radiation Oncology Conference Room, please utilize the hospital main elevators and take down to Level 2. When you arrive on Level two proceed forward, following the signs to the "green elevators". You will find the Radiation Oncology conference room on your right hand side, room HOS L2-664
                    [post_title] => Roche Oncology: Strategic Interests Presentation
                    [post_excerpt] => Join the Center for Biotechnology for a presentation on  Roche’s strategic interests in Oncology, the process for asset evaluation and the various partnership models available to support discovery and early development programs.
                    [post_status] => publish
                    [comment_status] => open
                    [ping_status] => open
                    [post_password] => 
                    [post_name] => roche-oncology-strategic-interests-presentation
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2019-04-05 19:57:03
                    [post_modified_gmt] => 2019-04-05 19:57:03
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://centerforbiotechnology.org/?p=3225
                    [menu_order] => 98
                    [post_type] => post
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [3] => WP_Post Object
                (
                    [ID] => 3954
                    [post_author] => 4
                    [post_date] => 2022-11-08 14:56:08
                    [post_date_gmt] => 2022-11-08 14:56:08
                    [post_content] => 
Apply for the first cohort of FY2023 by Nov. 16!



The I-Corps™ at NIH Program helps current Phase I SBIR/STTR awardees from the NIH and CDC transition from researcher to entrepreneur.



This 8.5-week training program provides practical guidance from experienced industry professionals that will move you forward on your path toward commercialization. Past participants have written strong SBIR/STTR Phase II applications, won partnerships and investments, and built vast networks in the field.



Apply for the first cohort of FY2023 through the NIH ASSIST platform by 5:00 p.m. your local time on Wednesday, November 16. 



Questions? Review the FAQs or contact us if you need help at icorps@mail.nih.gov.



Learn More and Apply: https://sbir.cancer.gov/commercialization/business/icorps





                    [post_title] => NIH iCorps: Apply by Nov. 16
                    [post_excerpt] => Apply by 11/16 to joing the I-Corps™ at NIH Program helping current Phase I SBIR/STTR awardees from the NIH and CDC transition from researcher to entrepreneur.
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-icorps-apply-by-nov-16
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-12-13 17:01:52
                    [post_modified_gmt] => 2022-12-13 17:01:52
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://centerforbiotechnology.org/?p=3954
                    [menu_order] => 13
                    [post_type] => post
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [4] => WP_Post Object
                (
                    [ID] => 3658
                    [post_author] => 3
                    [post_date] => 2021-03-22 14:57:42
                    [post_date_gmt] => 2021-03-22 14:57:42
                    [post_content] => 
Tools that accelerate medical countermeasure screening and development are vital to improving human health – from enabling personalized medicine to responding to health security threats such as pandemics. To this end, BARDA, in partnership with the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health, has launched the new ImmuneChip+ program. 



We aim to partner with innovators to support the development of advanced microphysiological systems / tissue chip platforms that integrate a component of the human immune system. The objective of the program is to develop a set of set of mature ImmuneChips, combining a previously validated model of a vital human tissue (e.g. lung, heart, kidney) with an immune system component, in a single platform that can be machine-manufactured and that includes multiple in-line sensors for long-term tissue monitoring. With this program, we aim to further enhance the usability of tissue chips and position them as useful tools in the drug development process and for personalized therapeutics.



For more details, please visit BARDA DRIVe program at https://drive.hhs.gov/immunechip.html 

                    [post_title] => BARDA: Immunechip+ Program Overview
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => open
                    [ping_status] => open
                    [post_password] => 
                    [post_name] => barda-immunechip-program-overview
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-03-22 15:01:19
                    [post_modified_gmt] => 2021-03-22 15:01:19
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://centerforbiotechnology.org/?p=3658
                    [menu_order] => 53
                    [post_type] => post
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

        )

    [post_count] => 5
    [current_post] => -1
    [before_loop] => 1
    [in_the_loop] => 
    [post] => WP_Post Object
        (
            [ID] => 4804
            [post_author] => 4
            [post_date] => 2025-03-20 12:10:54
            [post_date_gmt] => 2025-03-20 16:10:54
            [post_content] => 
The Center for Biotechnology is pleased to announce a request for proposals for our Research Evaluation and Commercialization Hub (REACH) award program. Awards will be in two categories: Feasibility ($50k/12mo) and Proof of Concept ($100K/12 mo.) Details on the full funding program overview and proposal guidelines can be found here.



The development of promising innovations often stalls due to limited early-stage funding to address translational uncertainties. The Center for Biotechnology's Research Evaluation and Commercialization Hub (REACH) award program bridges the translation gap between biomedical discovery and their development toward commercial goals. Program funding is intended to determine feasibility, develop proof-of-concept, and ultimately lead to follow-on funding, a strategic partnership, or company formation.



The REACH program supports faculty and postdoctoral researchers in translating bio-based, bio-convergence, and bio-medical research discoveries by providing targeted funding and strategic guidance to bridge the translation gap between discovery and development for commercialization.



Application Deadline: May 15, 2025, 5pm ET



Learn more about the program, get information session details and access the full request for proposals here: https://centerforbiotechnology.org/what-we-do/technology-development/reach/

            [post_title] => Funding Opportunity: Research Evaluation and Commercialization Hub (REACH)Awards
            [post_excerpt] => The Center for Biotechnology is pleased to announce a request for proposals for our REACH award program.  Awards will be in two categories: Feasibility ($50k/12mo) and Proof of Concept ($100K/12 mo.) 
            [post_status] => publish
            [comment_status] => open
            [ping_status] => open
            [post_password] => 
            [post_name] => news-reach25
            [to_ping] => 
            [pinged] => 
            [post_modified] => 2025-03-24 12:11:36
            [post_modified_gmt] => 2025-03-24 16:11:36
            [post_content_filtered] => 
            [post_parent] => 0
            [guid] => https://centerforbiotechnology.org/?p=4804
            [menu_order] => 0
            [post_type] => post
            [post_mime_type] => 
            [comment_count] => 0
            [filter] => raw
        )

    [comment_count] => 0
    [current_comment] => -1
    [found_posts] => 265
    [max_num_pages] => 89
    [max_num_comment_pages] => 0
    [is_single] => 
    [is_preview] => 
    [is_page] => 
    [is_archive] => 
    [is_date] => 
    [is_year] => 
    [is_month] => 
    [is_day] => 
    [is_time] => 
    [is_author] => 
    [is_category] => 
    [is_tag] => 
    [is_tax] => 
    [is_search] => 
    [is_feed] => 
    [is_comment_feed] => 
    [is_trackback] => 
    [is_home] => 1
    [is_privacy_policy] => 
    [is_404] => 
    [is_embed] => 
    [is_paged] => 
    [is_admin] => 
    [is_attachment] => 
    [is_singular] => 
    [is_robots] => 
    [is_favicon] => 
    [is_posts_page] => 
    [is_post_type_archive] => 
    [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0
    [query_vars_changed:WP_Query:private] => 
    [thumbnails_cached] => 
    [allow_query_attachment_by_filename:protected] => 
    [stopwords:WP_Query:private] => 
    [compat_fields:WP_Query:private] => Array
        (
            [0] => query_vars_hash
            [1] => query_vars_changed
        )

    [compat_methods:WP_Query:private] => Array
        (
            [0] => init_query_flags
            [1] => parse_tax_query
        )

)